Tetra Bio-Pharma

Tetra Bio-Pharma is a Canadian-based biopharmaceutical company specializing in the development of cannabinoid-derived medicines. The company focuses on drug development programs targeting inflammation, pain, ophthalmology, and oncology. Tetra Bio-Pharma’s therapeutic areas include sepsis, acute respiratory distress syndrome, cytokine release syndrome (COVID-19), breakthrough cancer pain, uncontrolled cancer pain, uveitis, proliferative vitreoretinopathy, chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, and hepatocellular carcinoma. The company employs multiple delivery systems for its robust pipeline and is committed to conducting rigorous clinical trials to ensure the commercialization of products based on scientific evidence and safety data required for the pharmaceutical industry. Tetra Bio-Pharma is listed on the TSX under the ticker TBP and on the OTCQB under the ticker TBPMF. The company collaborates with various strategic partners, including Altasciences, Alternavida Group, Altus Formulation, Azevedos Group, Cellvera, DanCann Pharma A/S, George Mason University National Center for Biodefense and Infectious Diseases, Innomar Strategies, IntelGenx Corp., Kamada Ltd., McGill University, NSERC, PREPAIRE, Ontario Lung Association, Targeted Pharmaceuticals Inc., and the New Brunswick Health Research Foundation. Tetra Bio-Pharma and the New Brunswick Health Research Foundation are jointly investing $1 million to establish a Health Research Chair in Cannabis at the University of New Brunswick. The company is dedicated to providing new and improved healthcare solutions focused on patient outcomes, including prevention, treatment, and overall wellness. Tetra Bio-Pharma utilizes advanced medical devices, formulations, and delivery systems to optimize patient care and ensure the efficacy and safety of its pharmaceutical products. The company’s headquarters are located in Orleans, Ontario, Canada, with an additional office in Longueuil, Quebec, Canada.